PREMIER Biosoft and JEOL Enter Agreement
News Jun 06, 2013
PREMIER Biosoft and JEOL announce that they have signed a co-marketing agreement for MALDIVision, a MALDI Imaging Mass Spectrometry (MALDI IMS) data analysis tool. The collaboration aims to provide a comprehensive tool for advancing research involving marker studies, drug metabolite profiling, lipid and proteomics analysis using MALDI-IMS technology. Under this agreement, JEOL will promote MALDIVision along with its JMS-S3000 SpiralTOF™ Matrix Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometer.
MALDIVision visualizes and analyzes spatial distribution of analytes in a sampled tissue section. MALDIVision is the only tool on the market to seamlessly load and analyze imaging data files up to 20 GB. The program generates high quality reconstituted MALDI images in 2D and 3D based on the m/z value of target compounds. Users can overlay up to 10 MALDI images for visualization of spatial distribution of different compounds present in a sample.
According to Yoshihisa Ueda, the general manager of the Mass Spectrometry Business Unit JEOL Ltd., “Our JMS-S3000 SpiralTOF™ has the highest mass resolving power among any MALDI-TOFMS on the market. This imposes a unique challenge to the imaging data analysis software; the amount of information and, thus, the size of the imaging data from SpiralTOF is also the largest. After rigorous evaluation, we found that MALDIVision can process such data flawlessly. We are quite excited that, by combining SpiralTOF and MALDIVision, now we can offer a powerful and unique solution for the cutting edge research in life science and material science.”
“Mass Spectrometry is a rapidly growing platform for biomarker discovery. This collaboration will provide the research community, especially in the Asia-Pacific region, with a powerful tool to support mass spectrometry based imaging applications,” said Arun Apte, CEO at PREMIER Biosoft.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.